RT Journal Article
SR Electronic
T1 Estimating Under Reporting of Leprosy in Brazil using a Bayesian Approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.22.20109900
DO 10.1101/2020.05.22.20109900
A1 de Oliveira, Guilherme L.
A1 Oliveira, Juliane F.
A1 Andrade, Roberto F. S.
A1 Nery, Joilda S.
A1 Pescarini, Julia M.
A1 Ichihara, Maria Y.
A1 Smeeth, Liam
A1 Brickley, Elizabeth B.
A1 Barreto, Mauricio L.
A1 Penna, Gerson O.
A1 Penna, Maria L. F.
A1 Sanchez, Mauro N.
YR 2020
UL http://medrxiv.org/content/early/2020/05/23/2020.05.22.20109900.abstract
AB Leprosy remains an important health problem in Brazil - the country register the second largest number of new leprosy cases each year, accounting for 14% of the world’s new cases in 2019. Although there was increasing advances in leprosy surveillance worldwide, the true number of leprosy cases is expected to be much larger than the reported. Leprosy underreporting impair planning effective interventions and thoughful decisions about the distribution of financial and health resources. In this study, we estimated leprosy underreporting for each Brazilian microregion in order to guide effective interventions and resouce allocation to improve leprosy detection in the country. We extracted the number of new cases of leprosy from 2007 to 2015 and population and socioeconomic information from the 2010 Census for each Brazilian municipality and grouped data in microregions. We applied a Bayesian hierarchical model to obtain the best explicative model for leprosy underreporing using Grade 2 of leprosy-related disabilities as a proxy to explain the incidence rates. Then, we estimated the number of missing leprosy cases (underreported cases) and the corrected leprosy incidence rates for each Brazilian microrregion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by The Medical Research Council (MR/N017250/1), CONFAP/ESRC/MRC/BBSRC/CNPq/FAPDF - Doencas Negligenciadas (FAP-DF to Gerson O. Penna, (Number 193.000.008/2016). Wellcome Trust (202912/B/16/Z), the funders of the study had no role in the design, data collection, analysis, interpretation, or writing the article. JFO was supported by the Center of Data and Knowledge Integration for Health (CIDACS) through the Zika Platform - a long-term surveillance platform for Zika virus and microcephaly (Unified Health System (SUS), Brazilian Ministry of Health).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committees of the University of Brasilia (UnB) (1.822.125), Instituto Goncalo Muniz - Fiocruz (1.612.302), and London School of Hygiene & Tropical Medicine (10580-1).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available as supplementary material.